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CORRESPONDENCE
Association of the Cannabinoid Receptor 2 (CB2) Gln63Arg Polymorphism with Indices
of Liver Damage in Obese Children: An Alternative Way to Highlight the
CB2 Hepatoprotective Properties
To the Editor:
We read with great interest the article by Teixera-Clerc et al.,1
regarding the hepatoprotective properties displayed by cannabinoid
receptor 2 (CB2) agonists in a mouse model of carbon tetrachlor-
ide (CCl4)-induced liver injury. Acute hepatitis induced by CCl4
was accelerated in CB2 knockout mice, resulting in increased
serum alanine aminotransferase (ALT) and aspartate aminotransfer-
ase (AST) levels compared to wild-type (WT) animals. Conversely,
the ALT and AST levels were reduced in CCl4-treated WT mice
following the treatment with the CB2 agonist JWH-133.
In apparent disagreement with these results, the same group
previously demonstrated that, in the liver of obese mice which
were fed a high-fat diet, CB2 stimulation potentiated insulin resist-
ance and nonalcoholic fatty liver disease (NAFLD), whereas CB2
inactivation reduced liver inflammation.2 In obese children,
NAFLD ranges from simple liver steatosis to steatosis associated
with inflammation and increased liver enzymes, which may eventu-
ally progress to liver cirrhosis.3
To highlight the role of CB2 in NAFLD progression, we took
advantage of a functionally relevant CB2 polymorphism. We stud-
ied the rs35761398 variant of the CNR2 (cannabinoid receptor 2;
GeneID 1269) gene, encoding for the CB2 receptor, which causes
the substitution of a glutamine with a positively charged arginine
at codon 63, in the first intracellular signaling loop. Receptor
carrying arginine shows reduced function when activated by an
endogenous cannabinoid.4
The variant was screened by direct sequencing in 438 Italian
obese children with liver steatosis at ultrasound imaging in order
to evaluate the association of the CB2 receptor Gln63Arg (Q63R)
functional variant with serum AST and ALT levels. Results from
this analysis (Table 1) demonstrate that the less functional R63
variant is statistically associated with higher ALT and AST levels
independent of sex, age and pubertal stage. The variant is not asso-
ciated with Body Mass Index, insulin resistance (assessed by Home-
ostasis Model Assessment of Insulin Resistance score) and size of
abdominal fat (assessed by waist-to-hip ratio).
To be homozygous for the R63 allele results in a significant risk
factor for liver damage, with an odds ratio for ALT >40 of 2.7
(95% confidence interval ¼ 1.65-3.92, P ¼ 0.001).
These data, obtained using an approach (i.e., association study
in humans) completely different from that of previously published
studies (i.e., analysis in murine models), showing that the partially
inactive R63 CB2 variant is associated with liver damage progres-
sion in obese children with liver steatosis, corroborate the idea of a
hepatoprotective role for CB2 receptors.
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Reply:
We thank Rossi and colleagues for their interest in our experi-
mental findings delineating the impact of CB2 receptors in experi-
mental models of liver injury. We reported recently that the hepatic
cannabinoid receptor 2 (CB2) displays beneficial hepatoprotective
and antifibrogenic properties.1,2 However, as stressed by Rossi and
colleagues, we also demonstrated that treatment of obese mice with
the CB2-selective agonist JWH-133 enhances insulin resistance and
steatosis.3 Deleterious effects of CB2 agonism in obese mice were
attributed to a proinflammatory effect of adipose tissue CB2 recep-
tors.3 However, our recent findings in a model of alcoholic liver
injury indicate that stimulation of hepatic CB2 receptors reduces
the development of fatty liver.4 Altogether, our experimental data
demonstrate the protective effects of hepatic CB2 receptors against
liver injury, steatosis, and fibrosis.
Table 1. Clinical and Laboratory Characteristics of 438
Obese Children with Liver Steatosis Stratified by
Cannabinoid Receptor 2 Q63R Genotype
Characteristic QQ QR RR P Values
N (%) 27 (7.5) 222 (50.7) 189 (41.8)
Females (%) 14 (53) 115 (52) 102 (54)
Prepubertal (%) 13 (48.1) 111 (50) 93 (49.2)
Age (years) 10.7 6 1.9 11.3 6 2.6 11.4 6 3.2 0.29
BMI SDS 2.9 6 0.4 3 6 0.6 3.1 6 0.7 0.043
W/Hr 0.65 6 0.03 0.64 6 0.05 0.65 6 0.07 0.16
HOMA-IR 5.7 6 3.4 6.5 6 4.8 6.6 6 4.3 0.78
ALT (U/L) 24.4 6 8.6 32.3 6 16.4 37.2 6 21.4 0.0001
AST (U/L) 22.5 6 6.5 24.5 6 7.0 27 6 13.2 0.002
Values are expressed as means 6 standard deviations. General linear model
(GLM) analysis, including sex, pubertal stage, and age as covariates, has been
used to compare continuous variables. Abbreviations: BMI-SDS, body mass
index standard deviation scores; W/Hr, waist circumference to height ratio;
HOMA-IR, homeostatic model of assessment of insulin resistance index.
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In their cohort study of over 400 obese children, Rossi and col-
leagues show a positive correlation between the presence of a CB2
variant with reduced activity, as assessed in culture studies, and the
degree of liver injury estimated by serum aminotransferase levels.
These interesting findings constitute the first evidence supporting the
clinical relevance of hepatoprotective effects of CB2 receptors. Fur-
ther studies should be conducted to examine the impact of CB2
polymorphism on the severity of liver lesions (steatosis, necroinflam-
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Stem Cells or Macrophages: Which Contribute to Bone Marrow Cell Therapy for Liver Cirrhosis?
To the Editor:
The experimental studies and clinical trials of bone marrow
(BM) cell therapy for severe liver diseases have been studied exten-
sively, although the benefit is controversial, and the underlying
mechanisms remain undefined.1 With great interest, I read the arti-
cle by Thomas et al.,2 who demonstrated that BM-derived differ-
entiated macrophage cell therapy improves structural and func-
tional parameters of experimental chronic liver injury. Their results
have identified defined single cell types from BM that have benefi-
cial effects on liver fibrosis. Their study can be hailed as an original
contribution in terms of understanding the mechanisms of BM cell
therapy for liver fibrosis.
However, other previous studies on BM cell therapy for liver
cirrhosis have focused on stem cells that may work by hepatic dif-
ferentiation or paracrine effects.3 Which kind of cells in the BM
may contribute to cellular therapy for liver cirrhosis: stem cells,
macrophages, or both? Here, we would like to offer our concerns
regarding this proposed therapy. First, in the report by Thomas
et al., the stem cells therapy group was not set to be compared
with groups treated with differentiated macrophages. Thus, the
different effects of these two kinds of cells on liver injury cannot
be known under the same conditions. Furthermore, animal exper-
imental studies have indicated that BM cell-derived stem cell
therapy for liver fibrosis is under debate. Nevertheless, some opti-
mistic results can be found in recent clinical trials reports,4
although safety and efficacy should be further demonstrated.
Because there are many differences between mice and humans,5
more rational and legalized clinical trials based on BM-derived
stem cells or macrophages should be encouraged. In addition,
BM is composed of a variety of cell types such as hematopoietic
stem cells, mesenchymal stem cells, and macrophages. BM cell
therapy function may depend on synergistic effects of several
kinds of cells, rather than defined single cell types. Thus, experi-
mental studies based on single and combinations of cell types
also need to be performed. Moreover, both posttransplant BM-
derived differentiated macrophages and stem cells are in transient
cell states that may only give short-term relief for liver fibrosis.
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Reply:
We thank Liu and colleagues for their comments; however, it is
important to clarify a number of points.
This was not a comparative study of stem cells versus differ-
entiated cells.1 Bone marrow (BM) contains a wide range of cell
types with potentially diverse actions when delivered during
liver injury. Positive effects have been detected following the
application of stem/progenitor cell containing BM fractions of
varying purity and potency.2,3 In our experiments, unfractio-
nated BM delivery caused a net increase in murine liver fibro-
sis.1 This phenotype is likely to be the result of several (interact-
ing and opposing) BM cell populations. BM stem cells,
including hematopoietic and mesenchymal stem cells, constitute
a numerically small minority of BM cells. Importantly, injected
mesenchymal stem cells can give rise to profibrogenic liver cell
populations,4,5 highlighting the potential risks of uncharacter-
ized cell populations.
The advantages of a single differentiated cell type in terms of
predictability and mechanistic clarity do not preclude the potential
therapeutic benefits of mixed cell fractions. However, for the field
to progress, we need to understand the precise activities of individ-
ual donor cell lineages before we can make sense of the potentially
diverse effects of mixed BM fractions.
BM stem cells or their derivatives may have benefit in chronic
liver disease. However, to date, clinical studies have been small or
uncontrolled, hence larger, randomized controlled trials are now
required to determine whether there are positive or negative clinical
effects. Indeed, adverse events have already been detected following
autologous BM cell infusion.6 To this effect, we are part of a mul-
ticenter randomized trial testing CD133þ hematopoietic stem cells
in cirrhosis that has already opened in the United Kingdom
(ISRCTN: 91288089).
Regarding the possibility of BM stem cells transdifferentiating
in vivo into hepatocytes, this has repeatedly been shown not to
occur to any meaningful degree, if at all. Therefore, paracrine
mechanisms of action are more plausible.7,8
The chronology of human cirrhosis is measured in years, so
clinically useful disease-modifying treatments may require repeat
administration. Furthermore, it is possible that cell-based treat-
ments will ultimately be tailored to parameters such as disease
etiology and stage of disease, necessitating a broad and well-under-
stood therapeutic arsenal.
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Virological Breakthrough and Resistance in Patients with Chronic Hepatitis B Receiving
Nucleos(t)ide Analogues in Clinical Practice
To the Editor:
We read with interest the article by Hongthanakorn et al.
published in a recent issue of HEPATOLOGY.1 The authors
reported a very high incidence of virological breakthrough
(VBT) in patients receiving five different nucleos(t)ide analogues
(NUCs) in clinical practice: 26% (39 patients). They reported
that 7% of NUC-naı̈ve patients receiving entecavir (ETV) expe-
rienced VBT, and that the cumulative probability of experienc-
ing VBT at 3 years was 13%.
The VBT rates reported by Hongthanakorn et al. are higher
than described previously. In our population of 69 NUC-naı̈ve
chronic HBV patients treated in routine clinical practice with
ETV, we found that 100% achieved undetectable HBV DNA after
96 weeks of treatment.2 We did not perform tests to evaluate
genetic resistance, but we found no evidence of clinical resistance
to treatment or VBT. Other studies in clinical practice have shown
high efficacy of treatment with low rates of VBT, around 1%.3-5 In
phase 3 randomized clinical trials, VBT rates with ETV treatment
were 1.6%.6,7
Hongthanakorn et al. argue that ‘‘medication adherence is likely
to be lower in clinical practice than in phase 3 clinical trials, where
highly motivated patients are recruited and closely monitored’’ and
that ‘‘patients with CHB receiving NUC therapy who experienced
VBT should be counseled on medication adherence.’’1 We agree
that adherence is crucial in the efficacy of treatment, but we have
demonstrated that a high adherence rate and treatment efficacy can
be obtained in clinical practice.
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Reply:
We appreciate Dr. Ridruejo and colleagues’ interest in our article. We
would like to clarify that the high rate of virological breakthrough we
observed in our practice does not mean that nucleos(t)ide analog treat-
ment is ineffective in suppressing hepatitis B viral (HBV) replication. Ta-
ble 2 showed that 71% of patients (53% HBeAg-positive) had undetect-
able HBV DNA at 1 year, similar to what had been reported in clinical
trials. The point that we wish to make is that during long-term treat-
ment, transient virological breakthroughs are common and some of these
episodes of breakthrough are related to medication nonadherence rather
than antiviral drug resistance, particularly when antiviral drugs with high
genetic barrier to resistance are used. Confirmation of virological break-
through and/or testing for drug resistance mutation would avoid
unnecessary changes to the treatment regimen. Because of the transient
nature of some of these breakthroughs, the frequency with which they
are observed depends on the frequency of HBV DNA monitoring. In
our practice, HBV DNA is monitored every 3 months throughout the
course of treatment. The rates of breakthrough would likely be lower if
our patients were monitored every 6 months or less often.
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Clinical Correlation of miR-375 and Alpha-Fetoprotein in Hepatocellular Carcinoma:
Comparison in Mice and Humans
To the Editor:
We read with great interest the article by Kowalik et al.,1
recently published in HEPATOLOGY. The authors found that hepato-
cellular carcinomas (HCCs) developed in mice that were adminis-
tered diethylnitrosamine and then repeatedly treated with the mito-
gen 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene. These mice
showed increased expression levels of the transcriptional coactivator
Yes-associated protein (YAP), and these increased expression levels
were associated with the down-regulation of miR-375 expression,
which is known to control YAP expression,2 and with enhanced
levels of alpha-fetoprotein (AFP), which is encoded by the target
gene of YAP. However, the inverse association between miR-375
and AFP expression was not dose-dependent. We describe our sin-
gle-center experience with 157 HCC patients who underwent pri-
mary resection. The patients were divided into two groups on the
basis of the mean levels of miR-375 expression in all tumor tissues,
which were determined using an miRNA array and validated by
real-time polymerase chain reaction (PCR) analysis. Ten samples
from living donor livers (mean [SD] miRNA expression, 13.85
[0.57]) were used as controls. miR-375 expression was down-regu-
lated in HCCs. The clinicopathologic characteristics of the patients
are summarized in Table 1. We found that preoperative serum
AFP levels in the group showing less reduction in miR-375 expres-
sion were significantly higher than those in the group showing
higher levels of reduction in miR-375 expression. The findings for
the other factors were comparable in both groups. In summary,
our results suggest that AFP expression in HCCs was not solely
regulated by the axis of miR-375-YAP-AFP.
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Expression n 5 71
Low Reduction
in miR-375
Expression n 5 86 P Value
miR-375 expression,
mean 6 SD
10.52 6 1.02 13.19 6 0.74 0.003
Mean age 6 SD
(years)
59.4 6 12.6 59.0 6 12.3 1.00
Sex (male) 55/71 67/86 1.00
Tumor size 6 SD
(cm)
4.7 6 3.0 4.2 6 2.9 0.63
Cirrhosis 30/71 42/86 0.41
HBV 49/71 63/86 0.6











Portal vein thrombosis 20/70 22/86 0.72
Preoperative AFP
expression,
mean 6 SD (ng/mL)
2089.3 6 11347.4 4748.2 6 16552.6 0.047
Abbreviations: HCC, hepatocellular carcinoma; SD, standard deviation; HBV,
hepatitis B virus; HCV, hepatitis C virus; AFP, a-fetoprotein.
enlargement and hepatocellular carcinoma development in mice. HEPA-
TOLOGY 2011;53:2086-2096.
2. Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling
effector YAP in liver cancer and inhibits tumor properties. Biochem
Biophys Res Commun 2010;394:623-627.
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Reply:
We read with great interest the letter by Ho et al., comment-
ing on our study about the increased expression levels of Yes-
associated protein (YAP) in chemically induced mouse hepato-
cellular carcinomas (HCCs).1 These increased expression levels
were associated with down-regulation of microRNA-375 (miR-
375) expression, which is known to control YAP expression,2
and with enhanced levels of alpha-fetoprotein (AFP), which, in
two independent studies, was found to be a target gene of
YAP.3,4 Ho et al. in their letter show that in 157 HCC, divided
into two groups on the basis of the mean levels of miR-375
expression, serum AFP levels were significantly higher in the
group showing less reduction in miR-375 than in the group
showing stronger reduction of miR-375. Based on these find-
ings, the authors suggest that AFP expression in HCCs is not
solely regulated by the axis of miR-375-YAP-AFP. We totally
agree with this conclusion. Indeed, as shown in our article,
while an anti-correlation exists between miR-375 and YAP
expression, such an inverse relation could not be observed
between miR and AFP, and nowhere in the text did we imply
that a YAP increase could be the main mechanism responsible
for AFP regulation. AFP is a well-known marker of HCC and
its increase is considered the result of a loss of differentiation of
cancer cells. Thus, it seems clear that the increased levels of AFP
cannot be due simply to up-regulation of YAP, but rather to a
general change in the several factors regulating this protein.
Interestingly, the article that originally described AFP as a target
gene of YAP was based on a transgenic mouse model where
YAP overexpression was induced in newborn (3-week-old) ani-
mals.3 Thus, it is possible that the increased AFP expression
observed in YAP-overexpressing mice could also be due to YAP-
dependent alteration of hepatocyte differentiation.
In conclusion, we agree with Ho et al. that AFP expression in
HCCs is not solely regulated by the axis of miR-375-YAP-AFP. As
with most genes, many pathways and many mechanisms (both at the
transcriptional, posttranscriptional, and posttranslational levels) can
regulate the expression of a particular protein and this is surely true
also for AFP. What we said in our article is that YAP is among the
many factors that can contribute to this regulation.
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Human Hepatic Stellate Cells Are Liver-Resident Antigen-Presenting Cells
To the Editor:
We read with great interest the article published in this journal
by Schildberg et al.1 In this study, the investigators demonstrated
that hepatic stellate cells (HSCs) veto naı̈ve cluster of differentia-
tion (CD)8þ T-cell priming through a cell-contact–dependent
mechanism, and that this novel HSC function is dependent on
their activation state. High expression levels of CD54 on HSCs
correlated with impaired expression of interleukin (IL)-2 receptor
and IL-2 production in T cells. The take-home message of this
study is the identification of a direct role of HSCs in controlling
non-major histocompatibility complex (MHC)-restricted depend-
ent immune tolerance.
Although this study reveals a novel, interesting immunological
function of HSCs, here, we want to call attention also to their
potential role as antigen-presenting cells (APCs). Winau et al.2
demonstrated that HSCs are intrahepatic APCs activating T cells
and eliciting a multiplicity of T-cell responses. More recently,
Bomble et al.3 demonstrated that, even though the function of
HSCs as APCs might be secondary in healthy liver and reduced
during epithelial-mesenchymal transition, in vitro stimulation with
interferon gamma (IFN-c) induces the expression of MHC class II
and restores their antigen-presenting functionality.
Here, we reinforce the data on the potential role of HSCs as
APCs by demonstrating that these cells express high levels of two
components of the antigen processing machinery: the endoplasmic
reticulum (ER) aminopeptidases, ERAP1 and ERAP2, which have
been shown to optimize precursor peptides for binding to MHC
class I molecules.4 As expected, the human HSC line, LX-2, in
basal conditions expresses high levels of surface MHC class I and
low levels of surface MHC class II molecules (Fig. 1A). IFN-c
stimulation resulted in the surface enhancement of both MHC
class I and MHC class II molecules. Interestingly, MHC class I
overexpression, also confirmed by immunoblotting, was associated
with the up-regulation of both ERAP1 and ERAP2 (Fig. 1B).
Altogether, these results, in agreement with previous studies,2,3
demonstrate that HSCs are liver-resident APCs with the capability
to induce hepatic T-cell immunity by MHC-restricted interaction.
Finally, these findings, as well as those presented by Schildberg
et al., suggest that therapeutic strategies aiming to recover or
increase MHC-restricted and/or non-MHC-restricted antigen-pre-
senting functionality of HSCs may provide opportunities to devise
immunotherapy strategies toward enhancing the ability of T lym-
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Fig. 1. IFN-c enhances antigen-processing/presenting functionality
of LX-2 cells. (A) Flow cytometric analysis of MHC class I and MHC
class II molecules in LX-2 cells grown in serum-free medium in the ab-
sence (gray lines) and presence (black lines) of 500 U/mL of IFN-c
for 6 days. Shaded histograms, isotype-matched negative controls. (B)
MHC class I, ERAP1, and ERAP2 immunoblotting in LX-2 cells treated
as in (A) ERp57 was used for normalization.
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Prominent Regulatory But Weak Antigen-Presenting Cell Function of Hepatic Stellate Cells
To the Editor:
In their commentary, Alisi et al. emphasize the function of
hepatic stellate cells (HSCs) as antigen-presenting cells (APCs)
besides their regulatory function.1 As indicated by Alisi et al.,
HSCs can, in principle, act as APCs for cluster of differentiation
(CD)4, CD8, and natural killer T cells.2 It remained unclear how
efficiently HSCs function as APCs relative to other hepatic cells,
in particular being located in the Dissé space next to liver sinusoi-
dal endothelial cells (LSECs), a well-documented liver-resident
APC.3
During conditions of direct competition in vivo, HSCs were
less efficient than LSECs in the uptake of circulating antigen
from the blood (Fig. 1A). Only dendritic cells (DCs) bear the
capacity to function as APC after the uptake of small amounts of
antigen. They employ antigen targeting through receptor-medi-
ated endocytosis into intracellular compartments dedicated to
cross-presentation in combination with antigen-persistence within
these compartments for efficient, prolonged antigen presenta-
tion.4,5 Other cells, such as macrophages, or LSECs need more
antigen uptake to cross-present antigen in a similar fashion,6,7
thus indicating that antigen processing is less efficient, compared
to DCs, but compensated by superior antigen uptake. Thus, we
next investigated the relative efficiency of HSCs to cross-present
antigen to CD8 T cells. Clearly, HSCs were again inferior to
LSECs in cross-presentation of circulating antigen ingested in
vivo (Fig. 1B). These results demonstrate that HSCs do not pos-
sess antigen-processing capability similar to DCs, suggesting that
if already antigen uptake is inefficient, downstream mechanisms,
such as peptide trimming in the endoplasmic reticulum (ER), are
unlikely to improve APC function. A recent report also showed
that primary HSCs have little, if any, APC function for CD4 T
cells, even after stimulation with exogenous interferon gamma.8
Taken together, these results demonstrate a hierarchy in the per-
formance of APC function for DCs being most efficient in anti-
gen processing, macrophages and LSECs compensating for ineffi-
cient antigen processing by high antigen uptake, and HSCs
showing low antigen uptake and inefficient antigen processing.
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Outcome of Patients Suffering from a Spontaneous Reactivation of Hepatitis B Presenting as
Acute-On-Chronic Liver Failure and Treated with Antivirals
To the Editor:
We read with great interest Garg et al.’s article1 published
in HEPATOLOGY. The authors conducted a randomized study
to compare the efficacy of tenofovir disoproxil fumarate
(TDF) therapy and placebo therapy in patients suffering from
a severe spontaneous reactivation of chronic hepatitis B
(CHB) presenting as acute-on-chronic liver failure. They
reported a high overall mortality rate of 63.0% (17/27), with
rates of 43% and 85% in the TDF and placebo arms,
Fig. 1. (A) Antigen-uptake by LSECs or HSCs isolated 1 hour after
challenge with fluorochrome-labeled ovalbumin (OVA; 4 lg). (B) IL2
release from B3Z-cells recognizing OVA-derived SIINFEKL on H-2Kb af-
ter 18 hours coculture with LSECs or HSCs, isolated from mice 1 hour
after injection of 1 mg of OVA.
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respectively. TDF significantly reduced the mortality rate and
hepatitis B virus DNA levels and improved the Child-Tur-
cotte-Pugh and Model for End-Stage Liver Disease (MELD)
scores in these patients at 3 months.
It is noteworthy that some patients with cirrhosis were
enrolled. First, we consider 3 months of observation to be
too short for determining the survival of these patients. We
reexamined 96 patients with liver decompensation treated
with lamivudine in our previous study in Taiwan.2 Eight
patients (8.3%), two patients (2.1%), and three patients
(3.1%) died within 1, 1 to 3, and 3 to 6 months of lami-
vudine treatment, respectively. In other words, 23.1% of the
patients (3/13) who did not survive for 6 months died after
3 months of antiviral treatment. Villeneuve et al.3 reported
that 25% of their patients (1/4) without hepatocellular carci-
noma died from hepatic failure within 3 to 6 months of the
initiation of lamivudine treatment. Fontana et al.4 reported
that patients with decompensated cirrhosis were still dying
even after the first 6 months. Hence, the mortality rate is
possibly underestimated in Garg et al.’s study.1 The mean
baseline MELD scores (27 and 25 in the TDF and placebo
arms, respectively) reflect the fact that the patients enrolled
in their study had more severe liver disease. In HEPATOLOGY,
Liaw et al.5 reported lower mortality rates for patients with
CHB and decompensated liver disease who were treated with
TDF (4.4% or 2/45) or entecavir (9.1% or 2/22) by 48
weeks. The lower mortality rate is likely related to the
milder severity of the patients’ liver disease (the median
baseline MELD scores were 11 and 10.5 for the TDF and
entecavir arms, respectively). Hence, the earlier initiation of
nucleot(s)ide analogue therapy seems critical for these
patients.
Another issue is the design of this study of patients with
cirrhosis and CHB-related acute-on-chronic liver failure: a
placebo arm was included. With a lack of facilities for liver
transplantation, Garg et al.1 observed a high mortality rate,
and most deaths (82%) occurred because of progressive liver
failure that led to the development of multiorgan failure.1
With a mortality rate of 4% to 30% 6 to 12 months after
lamivudine, telbivudine, and entecavir therapy3-8 and with
significant improvements in the long-term survival of patients
with hepatic failure,4 it does not seem appropriate to include
a placebo arm in studies enrolling patients with cirrhosis
and critical liver failure. In the era of nucleot(s)ide analogue
therapy with more potent anti–hepatitis B virus effects, we
look forward to the results of more large-scale studies seek-
ing to clarify whether the efficacy can be improved, particu-
larly in patients with cirrhosis, CHB, and acute exacerbation,
who have a poorer prognosis.
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Lack of an Association Between an Apolipoprotein C3 Genetic Variant and
the Liver Fat Content in Patients with Type 2 Diabetes
To the Editor:
We read with great interest the article by Kozlitina et al.,1
who found no causal relationship between apolipoprotein C3
(APOC3) variants and hepatic triglyceride contents in middle-
aged men and women. These results are not in accordance with
a recent publication by Petersen et al.,2 who demonstrated that
C-482T and T-455C polymorphisms in APOC3 are associated
with nonalcoholic fatty liver disease (NAFLD) and insulin resist-
ance. Even though NAFLD is well known to be associated with
insulin resistance and diabetes mellitus, the link between certain
genetic polymorphisms, NAFLD, and insulin resistance is quite
complex. Indeed, the patatin-like phospholipase domain contain-
ing 3 (PNPLA3) polymorphism is strongly associated with NAFLD
but not with obesity or insulin resistance.3,4 In contrast, Petersen
et al. found that genetic variants in APOC3 are associated with the
liver fat content and insulin resistance; their results, however, have
not been confirmed by Kozlitina et al. We recently published a
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study confirming that in people with type 2 diabetes, the liver fat
content was related to the rs738409 PNPLA3 polymorphism.5 In
this discordant context, we set out to determine whether the liver
fat content, evaluated with proton magnetic resonance spectros-
copy, was associated with the rs2854117 APOC3 polymorphism in
this population. The study involved 253 patients with type 2 diabe-
tes. One hundred fifty-eight patients (62.4%) had steatosis (hepatic
triglyceride content >5.5%). In comparison with patients without
steatosis, patients with steatosis had a higher body mass index, a
higher visceral fat area, higher plasma alanine aminotransferase lev-
els, higher plasma triglyceride levels, and lower plasma adiponectin
levels.
The APOC3 rs2854117 variant was not associated with the
liver fat content in our population (Table 1). No associations were
found between this APOC3 variant and either the plasma triglycer-
ide levels or the visceral fat area. In accordance with the study
reported by Kozlitina et al.,1 our data for a specific population of
patients with type 2 diabetes and a high prevalence of NAFLD
suggest that the rs2854117 APOC3 genetic variant has little or no
impact on the liver fat content.
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Carnitine Palmitoyltransferase as a Potential Target for Treating Diabetes:
Is Inhibition or Activation Preferable?
To the Editor:
We have read with interest the recent article by Orellana-
Gavaldà et al.,1 who report that a long-term increase in he-
patic fatty acid oxidation (FAO) leads to a beneficial effect in
a mouse model of obesity and diabetes. This effect of
increased FAO is induced by the overexpression of carnitine
palmitoyltransferase 1A (CPT1A) or its malonyl–coenzyme A
insensitive mutant isoform (CPT1AM). With the reduction in
hepatic steatosis, there should be an accompanying increase in
insulin sensitivity. CPT1AM overexpression is the more effec-
tive treatment in this obese/diabetes phenotype animal model.
An important finding is that an increase in FAO during the
postprandial phase contributes to the overall effect; during
this time, endogenous CPT1A activity is reduced by a con-
comitant increase of malonyl–coenzyme A, its physiological
inhibitor. Greater FAO activity during the phase in which the
liver is primarily engaged in the synthesis of fatty acids and
triglycerides (TAGs) may lead to important long-term changes
in metabolic intermediates (i.e., acyl coenzyme A). These
intermediates may mediate the observed improvements in glu-
cose and lipid metabolism by affecting the complex network






(n 5 129) P Value
Age (years) 62.1 6 10.7 61.6 6 9.5 0.79
Body mass index (kg/m2) 34.5 6 6.5 33.9 6 6.9 0.90
Aspartate aminotransferase (IU/L) 24.1 6 18.1 22.9 6 11.4 0.89
Alanine aminotransferase (IU/L) 37.1 6 21.6 40.1 6 32.6 0.44
Plasma triglyceride level (mmol/L) 2.25 6 1.57 2.13 6 1.53 0.24
Adiponectin plasma level (lg/mL) 6.2 6 4.7 5.9 6 5.0 0.70
Visceral fat area (cm2) 267 6 109 273 6 89 0.42
Liver fat content (%) 10.4 6 8.5 10.7 6 8.9 0.84
Steatosis: liver fat content > 5.5% [n (%)] 76 (61.2) 82 (63.5) 0.79
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of transcriptional factors (i.e., peroxisome proliferator-activated
receptors, hepatocyte nuclear factor, and sirtuins).2 Further-
more, the lowering of liver TAG levels may be associated
with a reduction of TAG metabolic intermediates, which are
known to counteract insulin signaling.3 This article describes
a remarkable decrease in plasma glucose levels in CPT1AMþ/
þ db/db mice (genetically obese and diabetic mice). This
counterintuitive effect occurs in a murine model in which the
severe hyperglycemic condition is primarily dictated by an
increased rate of gluconeogenesis (GNG). Indeed, this meta-
bolic pathway is strongly dependent on increased FAO activ-
ity according to the following observations: it provides adeno-
sine triphosphate and reducing equivalents, and it increases
the intramitochondrial levels of acetyl coenzyme A, which is
an obligate allosteric activator of the key enzyme pyruvate
carboxylase in the GNG pathway.4
Metformin, a first-line therapy for type 2 diabetes,
depresses GNG via the reduction of intracellular adenosine
triphosphate contents.5 Also, an efficient way of reducing he-
patic GNG is the inhibition of CPT1A. We have recently
shown that selectively inhibiting CPT1A depresses GNG both
in vitro and in vivo and results in improvement in the dia-
betic phenotype for db/db mice; this is also accompanied by
improved insulin sensitivity in diet-induced obese mice.6 These
effects have been observed despite concomitant increases in liver
TAG levels. According to these metabolic considerations, promot-
ing FAO seems to conflict with the antidiabetic outcomes
reported in db/db mice expressing CPT1AM in the liver. An
analysis of the molecular mechanism or mechanisms underlying
the antidiabetic effects resulting from the greater activity of liver
FAO perhaps may open new approaches to modulating GNG in
type 2 diabetes. One scientific inaccuracy in this work is the er-
roneous report by the authors that b-hydroxybutyryl coenzyme A
in the liver is an intermediate of ketone body metabolism (see
Table 1 and p 825 of their article). D-b-Hydroxybutyrate is a ke-
tone body enantiomer oxidized through the formation of acetoac-
etate and not through its esterification to coenzyme A, whereas
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Vitamin D Deficiency May Link Diabetes and Liver Neoplasms
To the Editor:
I read with great interest the article by Chen et al.,1 who con-
firmed the association of diabetes with liver neoplasms and found
that the incidence of primary malignant neoplasms of the liver was
significantly higher in patients with diabetes versus control subjects.
Even though multiple factors should be responsible for the associa-
tion between diabetes and an increased risk of malignant neo-
plasms of the liver, I propose that vitamin D deficiency potentially
links the two disorders for the following reasons.
First, vitamin D levels have been found to be significantly lower
in diabetic populations versus subjects without diabetes.2,3 It has
been reported that vitamin D deficiency predisposes individuals to
type 1 diabetes and type 2 diabetes and may be involved in the
pathogenesis of both forms of diabetes.3,4 Second, vitamin D defi-
ciency has been proposed to contribute to high risks for various types
of cancers. An increasing number of epidemiological studies support
the hypothesis that vitamin D plays a role in cancer prevention.5,6
Therefore, it seems rational to infer that vitamin D deficiency may
account in part for the experimental finding of a higher incidence of
malignant neoplasms of the liver in patients with diabetes versus age-
and sex-matched control subjects. Moreover, if this hypothesis is
verified in future studies, vitamin D status optimization in patients
with diabetes may represent a potential strategy not only for improv-
ing the condition of patients with diabetes but also for lowering the
associated risk of malignant neoplasms of the liver.
HONG-FANG JI, PH.D.
Shandong Provincial Research Center for Bioinformatic Engineering and
Technique, Shandong University of Technology, Zibo
People’s Republic of China
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Profound Differences of MicroRNA Expression Patterns in Hepatocytes and Hepatoma Cell Lines
Commonly Used in Hepatitis C Virus Studies
To the Editor:
In their recent letter to the editor, Bensadoun et al. describe a
divergent IL-28B (interleukin-28B) genotype of hepatoma cell lines
including Huh7 and its derivatives.1 Because these cell lines are
commonly used in cell culture studies of hepatitis C virus (HCV)
and the IL-28B gene polymorphism is a predictive marker for the
outcome of HCV infection, their observations emphasize the im-
portance of cautiously interpreting infection studies performed in
vitro. Here, we extend their conclusions and report profound dif-
ferences in the microRNA (miRNA) expression between primary
human hepatocytes (PHHs) and Huh7 cell lines.
Cellular miRNAs are key regulators in posttranscriptional regu-
lation of gene expression. They can also directly participate in virus
replication or act indirectly by determining the expression level of
replication cofactors. To analyze whether the commonly used
Huh7 cell lines differ in their miRNA expression patterns, we
screened 883 human miRNAs using the Geniom Biochip miRNA
Homo sapiens (febit holding gmbh, Heidelberg, Germany). PHHs
isolated from human liver resections of two different patients were
used as reference. Figure 1 and Supporting Table 1 show the pro-
found differences not only between PHHs and hepatoma cell lines
but also between the cell lines. Remarkably, the liver-specific
miRNA122 that directly influences HCV replication both in cell
culture and in infected chimpanzees2-4 was one of the most differ-
entially expressed miRNAs. Furthermore, predictions of the gene
targets of the miRNAs from Fig. 1A by the Genetrail program
(freely accessible at http://genetrail.bioinf.uni-sb.de) identified a
number of host proteins whose differential expression is known or
expected to influence HCV replication (see Supporting Table 2 for
the complete target list). Because studies on host factor require-
ments for virus replication nowadays involve small interfering
RNA–mediated down-regulation of candidate proteins, and the
level of knockdown is influenced by protein abundance and
Fig. 1. MicroRNA patterns of primary human hepatocytes and HCV-permissive hepatoma cell lines. (A) Heat map of a hierarchical clustering
of miRNAs and samples. The analyzed cell type is indicated on the x-axis and the 19 most different human miRNAs are indicated on the y-axis.
Red color represents a high expression whereas green corresponds to a low expression of miRNAs. Relative expression levels are given in a rela-
tive scale from 0 to 10,000. Samples can mainly be separated into two clusters. The cluster on the left includes PHHs from two different donors
without liver disease (PHH1 and PHH2), and the cluster on the right includes the three analyzed hepatoma cell lines Huh7, Huh7.5, and Huh7
Lunet. (B) Color-coded correlation of the overall miRNA expression pattern of PHHs and three hepatoma cell lines. Strong resemblance is indi-
cated in yellow (1.0 equals 100%); no resemblance is given in dark blue.
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turnover and thus miRNA composition, one would expect that the
respective experimental results would be influenced by the host
cells used. The recent observations of non-overlapping screening
results for HCV host factors5 may well be related to corresponding
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Updated Management of Hepatocellular Carcinoma
To the Editor:
I read with interest the updated practice guidelines for the man-
agement of hepatocellular carcinoma (HCC) by the American
Association for the Study of Liver Diseases.1 It is undeniable that
the Barcelona Clinic Liver Cancer staging system has become
widely accepted in clinical practice. However, the management
options for each stage appear to be too rigidly restricted. For exam-
ple, percutaneous ethanol injection (PEI) can be considered for
patients with liver nodules that are inaccessible to radiofrequency
ablation, but in comparison with either treatment as monotherapy,
the combination of radiofrequency ablation and PEI has been
shown to be more effective for long-term survival.2 For intermedi-
ate-stage patients, transarterial chemoembolization (TACE) seems
to be the treatment of choice. However, in comparison with TACE
alone, the combination of TACE and PEI has been demonstrated
to prolong survival in patients with small lesions and in patients
with advanced lesions.3,4 On the other hand, although the use of
sorafenib in patients with advanced HCC has been proven to pro-
long survival, the reported partial response rate is only 2%, and no
patients have achieved a complete response.5 Our group has dem-
onstrated that an intra-arterial infusion of chemotherapy can lead
to a complete response in 9.4% of patients with advanced HCC
and to a partial response in 18.9%.6 Thus, for patients with
advanced HCC, an intra-arterial infusion of chemotherapy is a via-
ble alternative to sorafenib.
GIN-HO LO, M.D.
Digestive Center, Department of Medical Education
E-Da Hospital, I-Shou University, Kaohsiung, Taiwan
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